Lanthanum Carbonate
Drugs For Treatment Of Hyperkalemia and Hyperphosphatemia
- Drug class
- Drugs For Treatment Of Hyperkalemia and Hyperphosphatemia
- Availability
- Prescription only
- Routes
- Oral
- Markets covered
- 2
- Products on record
- 4
- FDA reports (12 mo)
- 155
Overview
Lanthanum Carbonate is an active pharmaceutical ingredient in the Drugs For Treatment Of Hyperkalemia and Hyperphosphatemia group (V03AE). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 3 | April 17, 2026 |
| US United States | FDA | 1 | August 1, 2024 |
GBUnited Kingdom· MHRA
3 products
Uses
Lanthanum is indicated in adult patients as a phosphate binding agent for use in the control of hyperphosphataemia in chronic renal failure patients on haemodialysis or continuous ambulatory peritoneal dialysis (CAPD). 78 mmol/L in whom a low phosphate diet alone is insufficient to control serum phosphate levels.
How to take
USUnited States· FDA
1 product
Uses
1 INDICATIONS AND USAGE Lanthanum carbonate chewable tablets are phosphate binder indicated to reduce serum phosphate in patients with end- stage renal disease (ESRD). Management of elevated serum phosphorus levels in patients with ESRD usually includes all of the following: reduction in dietary intake of phosphate, removal of phosphate by dialysis, and reduction of intestinal phosphate absorption with phosphate binders.
Lanthanum carbonate chewable tablets are phosphate binder indicated to reduce serum phosphate in patients with end- stage renal disease (ESRD). ( 1 )
How to take
Drug interactions
Known interactions involving Lanthanum Carbonate. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL045691781 · revised April 17, 2026
- [2]FDA DailyMed · 16b0e6f5-4fc9-44… · revised August 1, 2024 [PDF]
- [3]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.